MMEDF - Compass Pathways: Risky And Overvalued
- Compass Pathways is a biotech psychedelic medicine development and therapy company that has developed a synthetic formulation of psilocybin, COMP360, for combatting treatment-resistant depression.
- Received the highly-valuable FDA Breakthrough Therapy Designation for COMP360 trials and is currently in Phase 2a trials.
- Extensive clinical trial pipeline with 21 sites in 10 countries and partners, including King's College London, Stanford University, and more.
- Backed by PayPal co-founder Peter Thiel, ATAI Life Sciences, and arguably the top biotech investor, Joseph Edelman at Perceptive Advisors.
- With the recent hype in the psychedelic sector, Compass has become overvalued by 1.44x.
For further details see:
Compass Pathways: Risky And Overvalued